The protein product of the Multiple Endocrine Neoplasia Type I (MEN1) gene is thought to be involved in predominantly nuclear functions; however, immunohistochemical (IHC) analysis data on cellular localization are conflicting. To further investigate menin expression, we analyzed human pancreas (an MEN1 target organ) using IHC analyses and 6 antibodies raised against full-length menin or its peptides. In 10 normal pancreas specimens, 2 independently raised antibodies showed unexpected cytoplasmic immunoreactivity in peripheral cells in each islet examined (over 100 total across all 10 patients). The staining exhibited a distinct punctate pattern and subsequent immunoelectron microscopy indicated the target antigen was in secretory granules. Exocrine pancreas and pancreatic stroma were not immunoreactive. In MEN1 patients, unaffected islets stained similar to those in normal samples but with a more peripheral location of positive cells, whereas hyperplastic islets and tumorlets showed increased and diffuse cytoplasmic staining, respectively. Endocrine tumors from MEN1 patients were negative for menin, consistent with a 2-hit loss of a tumor suppressor gene. Secretory granule localization of menin in a subset of islet cells suggests a function of the protein unique to a target organ of familial endocrine neoplasia, although the IHC data must be interpreted with some caution because of the possibility of antibody cross-reaction. The identity, cellular trafficking, and role of this putative secretory granule-form of menin warrant additional investigation.
M ultiple endocrine neoplasia type I (MEN1) is an inherited, autosomal dominant syndrome in which patients develop parathyroid, pancreatic, gastroduodenal, and pituitary gland tumors. 1, 2 Germline MEN1 gene mutations are highly penetrant and affect the majority of those with a DNA alteration, generally starting in the third decade. Clinical management includes gene mutation testing, symptomatic treatment, and surveillance. 3, 4 Although MEN1 tumors are predominantly benign, a subset of duodenopancreatic neoplasms will metastasize and produce significant morbidity and mortality.
MEN1 was first described as a distinct syndrome by Wermer 5 in the 1950s and later became the subject of study by research groups worldwide. 5 In 1988, Larsson and colleagues in Sweden identified chromosome 11 as the location of the responsible gene, which was subsequently cloned and characterized in 1997. 6, 7 Studies since then show that the gene is mutated in germline in approximately 80% of affected MEN1 kindreds, as well as in a significant fraction of counterpart neuroendocrine tumors with somatic mutation. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] Biochemical and functional studies indicate that menin resides primarily in the nucleus and interacts with transcription factors, although there are also published reports that implicate the protein in other cellular processes and the most central partners in its actions remain to be confirmed. [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] The goal of the present study was to utilize immunohistochemical (IHC) analysis to investigate menin expression in normal and pathologic human pancreas specimens.
MATERIAL AND METHODS

Antibodies
Antipeptide antibodies were generated by injecting rabbits with peptides corresponding to amino acid sequence in human menin (Table 1) . Full-length menin (FLM) antibody was generated in rabbits using recombinant human menin produced in Escherichia coli.
All antibodies were affinity purified on columns with a peptide or recombinant FLM, respectively.
Tissue Specimens and Histopathologic Analysis
Human pancreatic tissue samples, after obtaining informed consent and from surgical resections or from autopsy, were from IRB-approved studies in the intramural program of the National Institute of Diabetes, Digestive, and Kidney Disease at NIH. Ten cases of histologically normal pancreatic tissue (containing over 100 total islets for evaluation) were studied. Further, 6 pancreas samples and 4 nonpancreatic endocrine tumors (3 parathyroid adenomas and 1 pulmonary carcinoid) from patients with MEN1 were examined, including 5 tumors from kindreds with known germline MEN1 mutations and allelic deletion encompassing the MEN1 locus on chromosome 11q13. 12, 13, 33 Tumor tissue and its MEN1 gene mutation were: 357del4, parathyroid tumor; 357del4, parathyroid tumor; K119del, pancreatic endocrine tumor (glucagonoma); 512delC, parathyroid tumor; and 512delC, pulmonary carcinoid.
The histologic and IHC sections were evaluated by a consensus of 2 pathologists (L.V.D. and M.R.E.B.) who used a definition of hyperplastic islet as an enlarged (Z250 mm) islet of normal or somewhat irregular shape. Tumorlets/microadenomas differed from hyperplastic islets based on their monotonous cellular content, trabecular/serpentine architecture, increased amount of collagen stroma, and were <0.5 cm in size. Lesions >0.5 cm were classified as islet cell tumors. 34 
IHC
IHC staining for menin in formalin-fixed, paraffinembedded (FFPE) sections was performed with 6 antibodies using an automated immunostainer (Ventana Medical Systems Inc. Tucson, AZ) according to the company's protocols, with slight modifications. Briefly, 5-mm-thick histologic sections were mounted on Fisherbrand/Plus Superfrost Precleaned slides (Fisher Scientific, Pittsburgh, PA) and attached by overnight heating at 581C. After deparaffinization and rehydration the slides were placed in a microwave pressure cooker in 0.01 mol/L citrate buffer (pH 6.0) containing 0.1% Tween 20 and heated in a microwave oven at maximum power (800 W) for 20 minutes and then cooled in Tris-buffered saline. Thereafter, all sections were incubated in Tris-buffered saline (pH 7.6) containing 5% normal goat serum (Cell Signaling Technology) for 40 minutes. The primary antibodies (1:2000 dilution for 498 and 1:300 dilution for FLM) were incubated overnight at room temperature.
The remainder of the procedure (secondary antibody, avidin-biotin complex, color development, and counterstain) was performed on a Ventana immunostainer. The sections were lightly counterstained in Mayer's hematoxylin and then mounted. Negative controls were established by replacing the primary antibody with buffer or with rabbit polyclonal immunoglobulin G (IgG) (Abcam, Cambridge, MA). Peptide competition experiments were performed for the FLM and 498 antibodies using the same protocol except the primary antibodies were preincubated with either FLM, 498-peptide, a menin C-terminal peptide (NHGRI 498), or a non-C-terminal peptide (NHGRI KM28) at a 50 Â molar concentration.
Immunoblots
Protein lysates were obtained from cell lines or a homogenized frozen pancreas using radioimmunoprecipitation assay buffer (Cell Signaling, Danvers, MA) containing a protease inhibitor cocktail (Sigma-Aldrich, St Louis, MO). Concentrations were measured using a protein assay dye reagent (BioRad, Hercules, CA). Following denaturation with b-mercaptoethanol, the lysates were run on a 10% BIS-TRIS polyacrylamide gel (Life Technologies, Carlsbad, CA) and transferred to polyvinylidene difluoride membranes (Amersham Parmacia Biotech, Piscataway, NJ). The membranes were blocked with Â 1 casein solution (Vector Laboratories, Burlingame, CA) and incubated with FLM (diluted 1:300) or 498 (diluted 1:2000) at 41C overnight. After brief washing and subsequent incubation with the secondary anti-rabbit IgG-HRP (Santa Cruz Biotechnology, Dallas, TX), the blots were developed using an enhanced chemiluminescence reaction (Amersham Pharmacia, Piscataway, NJ).
Cell Block Studies
HEK 293 cells were transfected with menin as previously described. 35 Briefly, the cells (ATCC, Manassas, VA) were grown in Dulbecco's modified Eagle's medium (Life Technologies, Carlsbad, CA) containing high glucose and glutamine supplemented with 10% fetal bovine serum (Gemini Bio Products, West Sacramento, CA), and a Â 1 concentration of antibiotic-antimycotic (Life Technologies, Carlsbad, CA) in a humidified incubator at 5% CO 2 at 371C. Transient transfection with pCMV-Sport-menin was carried out with Superfect (Qiagen, Germantown, MD). Both transfected and nontransfected cells were pelleted and processed into an FFPE cell block. 
Immunoelectron Microscopy
Tissue pieces were removed from a paraffin block, deparaffinized in xylenes, placed in absolute ethanol, and embedded in LR White (SPI, West Chester, PA). Ultrathin sections were mounted on 150-mesh uncoated nickel grids. Grids were floated on blocking solution [PBS, 0.1%; Tween 20, 0.5%; cold-water fish gelatin (Ted Pella Inc., Redding, CA)] for 20 minutes, incubated for 1 hour with a 1:100 dilution of the FLM antibody, rinsed in blocking buffer for 5 minutes, blocked with 2% goat serum, rinsed with blocking buffer, then incubated with 10 nm gold-conjugated secondary goat antibody (Ted Pella Inc.,), rinsed in PBS, and air dried. Sections were stained with aqueous uranyl acetate and examined with a Phillips CM10 electron microscope.
RESULTS
Six separate anti-menin antibodies were produced in rabbits and selected for study based on recognition of the protein on an immunoblot (Table 1) . One antibody was raised against FLM and 5 against peptides, including N-terminal (GPN), mid-protein (GEE), and C-terminal regions (SQV, 498, 620).
Overall, 4 of the antibodies (GPN, GEE, SQV, 620) did not generate consistent IHC results in islet or exocrine cells in archival clinical pancreas specimens and were not pursued further. In contrast, the FLM and 498 antibodies showed unexpected, punctate cytoplasmic staining that was uniquely observed in a subset of cells in all islets (over 100 total examined) in 10 cases of normal pancreas. The staining was present with both antibodies, but the quality and reproducibility varied. The FLM antibody provided clear, reproducible, and definitive results that were minimally affected by experimental conditions (Figs. 1A, B) , with mostly peripheral localization of immunoreactive cells in islets and strong positivity. Immunoelectron microscopy performed with the FLM antibody showed that the staining was localized to secretory granules (Fig. 1C) . Adjacent islet cells, exocrine pancreas, and nuclei were all negative by EM, consistent with the IHC findings.
Cytoplasmic islet cell staining was also observed using the 498 antibody; however, in contrast to FLM, the 498 staining was somewhat equivocal. The quality and reproducibility of the signal varied (sometimes showing cytoplasmic staining in islet cells and other times weak or noninterpretable staining with a diffuse brown background) depending on the experimental conditions and the particular 498 antibody-rabbit preparation (Figs. 1D-F) .
Control experiments for the FLM and 498 antibodies included competitive inhibition experiments using a Â 50 molar ratio of FLM or 1 of 3 menin peptides. Blocking of the FLM and 498 antibodies with whole menin and 498-peptide, respectively, eliminated islet cell staining, thus confirming the IHC results were because of Â40) . B, Section of pancreatic tissue surrounding a neuroendocrine tumor in a resection from an MEN1 patient. IHC staining demonstrates FLMimmunoreactive cells located at the periphery of islets that appear unremarkable when examined by light microscopy (original magnification, Â40). C, Section from a pancreatectomy specimen of an MEN1 patient demonstrates somewhat enlarged islets with peripheral FLM-immunoreactive cells, and a hyperplastic islet in the center with FLM-immunoreactive cells (original magnification Â 40). D, Section of pancreatic tissue from an MEN1 patient demonstrates increased numbers of periductal endocrine cells and a small islet budding from the duct (arrow), enlarged hypertrophic islets, and a small tumorlet that are all immunoreactive with FLM (original magnification, Â100). FLM indicates full-length menin; IHC, immunohistochemical analysis.
Appl Immunohistochem Mol Morphol Volume 22, Number 10, November/December 2014 Subcellular Localization of Menin a specific antibody-antigen reaction (results not shown). Islet staining with both antibodies was also blocked by an independent menin C-terminal peptide but was not affected by a non-C-terminal peptide at the same concentration, indicating that both the 498 antibody (as expected) and the FLM antibody recognize the C-terminus of the protein. Immunoblotting of a human pancreatic lysate with the FLM antibody showed a single band at approximately 63 kDa (Fig. 1G) , supporting the notion that the observed IHC staining was because of menin. Examination of pancreatic specimens from MEN1 patients showed a generally similar immunostaining pattern of unaffected islets as in normal control tissue, except for a more peripheral location of positive cells in some otherwise normal appearing islets ( Figs. 2A, B) . A spectrum of additional pathologic MEN1-related changes was also present and further highlighted by menin IHC staining, including: an increase in menin-positive islet precursor cells budding off pancreatic ducts; hyperplastic islets with increased numbers of menin-immunoreactive cells; and endocrine tumorlets/microadenomas with diffuse cytoplasmic menin staining that suggests an alteration in menin amount or subcellular location in these lesions (Figs. 2C, D) . An MEN1 islet cell tumor (glucagonoma; Fig. 3 ), 3 MEN1 parathyroid tumors, and 1 MEN1 pulmonary carcinoid with known biallelic MEN1 gene inactivation (see Materials and methods) were negative for menin staining with both the 498 and FLM antibodies, consistent with a 2-hit loss of a tumor suppressor protein, as the majority of MEN1 tumors delete the wild-type allele ( Table 1) . 33 As a control experiment to assess the staining sensitivity of the FLM antibody, HEK 293 cells with and without menin transfection were processed into a cell block by a standard FFPE method and analyzed by IHC. Nontransfected cells were negative for menin ( Fig. 4A) , although the cells showed the presence of the protein on an immunoblot. 35 In contrast, >50% of transfected cells showed strong nuclear staining, suggesting the protein is only detectable by IHC when present above a certain threshold (Fig. 4B) .
DISCUSSION
Previous biochemical studies suggest that menin resides in the cell nucleus and implicates transcription factor and other nuclear binding partners in the protein's function. 20, [35] [36] [37] In situ analysis performed by several groups also demonstrates nuclear localization of the protein, although the results depend on the particular antibody and/or technique employed (IHC vs. immunofluorescence) and the biological source of the sample (mouse vs. human). 35, [38] [39] [40] Alternatively, some published IHC reports describe cytoplasmic menin staining or a shuttling of the protein among cellular compartments. [41] [42] [43] The present study revealed strong granular cytoplasmic menin immunoreactivity in a subset of cells in normal human islets. Nuclear menin staining was neither observed in any endocrine, exocrine, or stromal cells, nor in nontransfected HEK cells, suggesting that IHC staining using our antibodies was not sensitive enough to measure endogenous nuclear menin in FFPE-processed cultured cells or clinical samples. In contrast, the cytoplasmic staining observed in patient specimens by IHC appears because of menin expressed at a high level in secretory granules, similar to insulin, glucagon, and other hormones that are abundant in islets.
IHC is an important technology for semiquantitative measurement of a protein across a histologic section; however, data must be interpreted conservatively as hybridization of an antibody to a surface-bound tissue matrix is a complex interaction. Thus, we approached the present IHC results with some caution, particularly as cytoplasmic menin expression in pancreatic endocrine cells was unexpected. To fully interrogate the IHC results, we performed all appropriate control experiments, including competitive inhibition, and these data were consistent with menin as the source of the immunoreactivity. Yet, it is important to note that these controls do not rule out the possibility of cross-reaction with a protein other than menin, although several observations argue against this possibility. For example, although the cellular and subcellular menin staining were similar to that of glucagon, strongly positive glucagon endocrine tumors were completely negative for menin ( Fig. 3) . Moreover, selective staining of only a subset of islet cells, as well as lack of tumor cell staining (tumors retain structurally normal granules), indicate it is unlikely our antibodies react with constitutive endocrine granule proteins as all islet cells and tumors should be positive if this were true.
Cross-reaction with one of the other pancreatic hormones (somatostatin, pancreatic polypeptide, ghrelin) is a theoretical possibility, but immature endocrine cells (budding off ducts) that do not produce these hormones were positive for menin. Finally, an immunoblot of frozen pancreatic tissue showed a single band corresponding to the known molecular weight of menin.
None of the anti-menin peptide antibodies, except 498 to some extent, produced strong, reliable, and nonequivocal results in FFPE samples. It is worth noting, at least in our experience, that antibodies produced against full-length proteins generally produce superior IHC staining compared with antipeptide antibodies, particularly for low abundant proteins measured in archival specimens. Thus, our generally poor results with the Islet cell hyperplasia, dysplasia, and ductuloinsular complexes in MEN1 have been previously described. 44 Our study identified a spectrum of pancreatic endocrine histopathology in MEN1 specimens and included increased numbers of menin-positive cells budding off ducts; menin-positive preneoplastic lesions (hyperplastic islets and tumorlets/microadenomas); and menin-negative endocrine tumors. Overall, these changes can be explained by a continuum model of tumor suppression 45 in which reduction in tumor suppressor gene dosage (haploinsufficiency) confers a new phenotype, and "one-hit" premalignant changes are a part of tumor progression. A recent report on changes in global gene expression observed in endocrine pancreas of young mice heterozygous for Men1 supports the notion that the gene acts as a haploinsufficient suppressor. 46 Similar to many familial cancer syndromes, affected members of MEN1 kindreds harbor a gene mutation in each cell in their body, yet only develop tumors in certain organs. 1,2 A simple mechanistic explanation is that normal physiological expression of menin is limited to precursor neoplastic cells, thus functional inactivation affects growth and produces tumors only in target endocrine glands. However, this is not what is observed experimentally as the MEN1 gene is ubiquitously expressed in cells and tissues at both the transcript and protein level. The etiology of inherited, organ-specific endocrine tumors appears complex, likely with at least 2 cellular roles for menin, one that is involved in all cells and a second that is unique to those that form neoplasms. Recent data on the 3-dimensional structure of menin demonstrates that along with sites interacting with MLL, JunD, and other nuclear proteins, it contains a helical palm domain with 3 tetratrico peptide repeat motifs predicting wide versatility of binding partners and corresponding cellular processes. 47 To date, there is no mechanistic explanation for the pattern of organ involvement observed in MEN1 patients and endocrine cell-specific functions of menin have not been identified, thus the present IHC data point to potential new, non-nuclear functions involved in tumorigenesis.
The secretory granule localization of menin observed by immunoelectron microscopy suggests the protein might function outside of the cell, or regulates hormones that do so. At first glance, a secretory/ extracellular role for menin seems unusual and differs significantly from most known tumor suppressor genes. However, endocrine hormones have multiple physiological effects on target cells, including growth; therefore, a hormone-related tumor suppressor activity for menin is not necessarily implausible, although the mechanism whereby archetypal, 2-hit inactivation of the MEN1 gene and corresponding loss of menin in secretory granules, in a single islet cell, resulting in endocrine tumorigenesis may not be simple or straightforward. One can hypothesize that autocrine or paracrine growth inhibition is the normal physiological role of secreted menin; thus, either haploinsufficiency or complete loss of function negates a normal feedback loop and produces increased cell division in the affected or neighboring cell(s). Or alternatively, menin may regulate other secreted growthinfluencing hormones in granules and its loss disrupts normal homeostasis in the islet more generally. As an example of this possibility, preliminary results suggest that menin interacts with prohormone convertase (PC1), a known regulator of insulin and other hormones that is also located in endocrine cell secretory granules (unpublished data). Further evaluation of the putative cytoplasmic form of menin and its role in endocrine cell tumorigenesis is warranted to address these and other questions.
